RGN-259
Phase 3Small molecule
RGN-259 is one of 30 small molecule programs targeting Dry Eye Syndrome. It is currently in Phase 3.
1
Indications
5
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
81 competitors in Dry Eye Syndrome
#DrugCompanyPhaseTrials
1Alphagan
AbbViePhase 3
Cyclosporine a
NovartisPhase 3
Sodium Hyaluronate
SanofiPhase 3
Cosentyx
NovartisPhase 2
Ilaris
NovartisPhase 2
Restasis
Aurinia PharmaceuticalsPhase 3
Cyclosporin a
NovartisPhase 2
NOVA22007
SSanten Inc.
Phase 3
HU007
HHuons Co., Ltd.
Phase 3
RGN-259
RReGenTree, LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dry Eye Syndrome3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RGN-259. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RReGenTree, LLC